강력한, 미세 유체 세포 내 전달 플랫폼으로 휴대 뒤쪽에서

Executive Industry Relevance

Vector-free intracellular delivery remains a critical bottleneck in therapeutic development, particularly for primary immune cells and hard-to-transfect cell types. This microfluidic squeezing platform enables direct cytosolic delivery of macromolecules and nanomaterials without chemical modification or specialized buffers, reducing mechanistic ambiguity in target validation. By improving delivery efficiency in challenging systems, the method supports predictive confidence in early discovery and de-risks translational pathways for immunotherapy and regenerative medicine applications.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables functional interrogation of therapeutic hypotheses in primary immune cells and reprogramming models.
• Operational Value: Provides a reproducible, buffer-free system for delivering transcription factors, antibodies, or nucleic acids to assess target engagement.
• Predictive Value: Supports go/no-go decisions by confirming intracellular delivery of effector molecules prior to functional assays.

Screening & Assay Development

• Scientific Value: Generates quantitative, flow-cytometry-based readouts of delivery efficiency across cell types and material concentrations.
• Operational Value: Standardizes sample preparation through controlled shear rates and device geometry, minimizing variability in high-throughput screens.
• Assay Readiness: Outputs delivery percentage and viability metrics that enable compound or material ranking in lead identification workflows.

Translational & Preclinical Research

• Translational Continuity: Bridges discovery-scale immune cell modulation to preclinical evaluation of enhanced anti-tumor efficacy.
• Mechanistic De-risking: Confirms cytosolic delivery of immunomodulatory proteins, reducing reliance on endogenous expression systems.
• Disease-Relevant Systems: Supports testing in primary T cells, dendritic cells, and stem cells relevant to cancer immunotherapy and regenerative medicine.

Pipeline & Workflow Integration

The method fits within the discovery-to-preclinical continuum, enabling hypothesis testing in early biology, assay-ready sample generation for screening, and mechanistic validation prior to in vivo studies.

• Discovery Biology: Facilitates target validation by delivering CRISPR components, siRNAs, or antibodies to confirm pathway involvement in immune activation or cell fate.
• Screening: Delivers libraries of nanomaterials or peptides to immune cells for uptake and functional screening under standardized shear conditions.
• Analytics: Provides flow cytometry-derived delivery efficiency and viability percentages as quantitative endpoints for condition comparison.
• Translational Research: Enables preclinical testing of engineered immune cells with delivered payloads to assess tumor-killing activity in co-culture models.
• Enterprise Reuse: Platform design allows reuse across cell types and payloads with only pressure and chip optimization, supporting scalable deployment in discovery and process development.

Operational & Enterprise Impact

• Scientific Value: Reduces false negatives in target validation by achieving delivery in primary and non-dividing cells where viral or lipid-based methods fail.
• Operational Value: Eliminates need for payload conjugation, specialized buffers, or viral production, simplifying workflow and reducing cost per condition.
• Strategic Value: Increases confidence in early-stage immunomodulatory candidates by confirming intracellular delivery before resource-intensive animal studies.
• Portfolio Impact: Enables risk-adjusted prioritization of delivery-dependent biologics, such as cytokine engagers or transcription factor therapies, based on achievable cytosolic concentrations.

Implementation Considerations

• Requires expertise in microfluidic device handling, cell suspension preparation, and pressure regulation to avoid clogging or excessive shear-induced death.
• Depends on access to microfluidic chips, pressure regulators, reservoir systems, and flow cytometry for readout; compatible with standard biosafety cabinet workflows.
• Necessitates standardization of cell concentration (1–10 million/mL), pre-straining through 40 µm filters, and incubation time (≤10 min post-delivery) for reproducibility across users and sites.
• Requires optimization of pressure (e.g., 70 PSI) and flow speed per cell type and chip design to balance delivery efficiency and viability, with viability loss typically <20% under optimized conditions.
• Limited by potential clogging from aggregates or debris, necessitating cell straining and regular chip exchange; performance varies with cell size, membrane stiffness, and payload molecular weight.

Biopharma FAQs